Close

SARS-CoV-2

Nucleocapsid Antibodies Appear to Be Long-Lasting After SARS-CoV-2 Infection

In a prospective, longitudinal study, N-antibodies peaked 90–100 days after infection and persisted for at least 500 days in most patients. The duration of antibody response after SARS-CoV-2 infection is not clearly established, although prior studies have estimated that antibodies produced after natural infection last from 3 to 6 months. […]

Read More

SARS-CoV-2 Could Be at Root of Mysterious Hepatitis in Kids

 A chain of events possibly triggered by unrecognized infection with the SARS-CoV-2 coronavirus could be causing the mysterious cases of severe hepatitis reported in hundreds of young children around the world, researchers suggest. Children with COVID-19 are at significantly increased risk for liver dysfunction afterward, according to a report posted […]

Read More

Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel

Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 infection.1 A previous study that described MIS-C cases in the first 3 waves of the COVID-19 pandemic found that the proportion of individuals with severe illness declined after the first wave.2 In Israel, the Omicron (B.1.1.529) variant started to spread […]

Read More

SARS-CoV-2 RNA Can Persist in Stool Months After Respiratory Tract Clears Virus

SARS-CoV-2, or at least pieces of it, sticks around longer in some infected individuals than respiratory sample testing would suggest, a recent study found. After respiratory samples tested negative, a small proportion of the 113 study participants continued to shed SARS-CoV-2 RNA in their feces—about 4% of them for at least […]

Read More

FDA Authorizes Pfizer’s COVID-19 Booster for Children Ages 5 to 11

The FDA expanded an emergency use authorization (EUA) today allowing the Pfizer-BioNTech COVID-19 booster shot for children between the ages of 5 to 11 who are at least 5 months out from their first vaccine series. According to the most recent data from the Centers for Disease Control and Prevention, […]

Read More

Mayo Clinic Q&A podcast: COVID-19 update

The widespread availability of at-home COVID-19 tests have made it easier for people to know if they have the virus, and to take measures to protect themselves and others. But there is a downside. Because the majority of tests are now done at home and often not reported, the official counts on […]

Read More

La calculadora de riesgo quirúrgico del American College of Surgeons es eficaz para pacientes mexicanos en el contexto de urgencias

Un equipo de médicos encontró que la calculadora de riesgo quirúrgico ACS NSQIP, del American College of Surgeons (ACS), predice la mayoría de complicaciones posoperatorias y estima los días de estancia hospitalaria de pacientes mexicanos operados en un escenario de urgencias.[1] Y aunque no fue eficaz para predecir neumonía, infección de vías urinarias o readmisión hospitalaria, […]

Read More

Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection […]

Read More
Translate »